COMPANY

Fzata

HQ: Halethorpe, MD source · fzata.com ↗

Location: Halethorpe, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

20NIH grants

Funding and NIH signals

NIH award NIH awarded $2.06M (NIH grant 4UH3NS135350-02, extension, notice Sep 19, 2026); 3 NIH awards totaling $2.74M in the last 12 months. NIH RePORTER 4UH3NS135350-02 (Sep 19, 2026)
Evidence (3 events)
- Sep 19, 2026 · NIH RePORTER 4UH3NS135350-02
  Organization: FZATA, INC.; City/State: HALETHORPE, MD; Project number: 4UH3NS135350-02; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 2058422; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome; Organization type: Domestic For-Profits
- Sep 17, 2026 · NIH RePORTER 1R44DK146567-01
  Organization: FZATA, INC.; City/State: HALETHORPE, MD; Project number: 1R44DK146567-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 372153; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Gut-Targeted IL-10 Delivery via Engineered Saccharomyces boulardii to Prevent Immune Checkpoint Inhibitor Colitis; Organization type: Domestic For-Profits
- Sep 11, 2026 · NIH RePORTER 1R44AI197301-01
  Organization: FZATA, INC.; City/State: HALETHORPE, MD; Project number: 1R44AI197301-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 313095; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a Dual-Action Oral Immunotherapy for Clostridioides difficile Prevention; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 19, 2026 Grant Government grant — NIH UH3: $2.06M (annual award, as published), announced Sep 19, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Sep 17, 2026 Grant Government grant — SBIR: $372,153 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Sep 11, 2026 Grant Government grant — SBIR: $313,095 (annual award, as published), announced Sep 11, 2026. Agency: NIH/NIAID. Source: government award database. source ↗

Funding

Last 2 years.

Sep 19, 2026 Government grant — NIH UH3: $2.06M (annual award, as published), announced Sep 19, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Sep 17, 2026 Government grant — SBIR: $372,153 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Sep 11, 2026 Government grant — SBIR: $313,095 (annual award, as published), announced Sep 11, 2026. Agency: NIH/NIAID. Source: government award database. source ↗

NIH awards 20

Annual award amounts. Total $18.3M.

Aug 29, 2024 NIH award 1UG3NS135350-01A1 FY2024: $2,091,549 awarded for that fiscal year; activity UG3 (OTHER_NIH); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A novel oral immunotherapy for chronic visce source ↗
Aug 10, 2023 NIH award 5R44AI136176-04 FY2023: $923,175 awarded for that fiscal year; activity R44 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Serological Assay for Neutralizing Antitoxin Respon source ↗
Apr 14, 2023 NIH award 5R44DK129133-03 FY2023: $950,520 awarded for that fiscal year; activity R44 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. Novel Oral Yeast Immunotherapies for Ulcerative Colit source ↗
Oct 24, 2022 NIH award 5R44AI155277-04 FY2023: $906,503 awarded for that fiscal year; activity R44 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Yeast-based Immunotherapy against Clostridioides di source ↗
Aug 11, 2022 NIH award 5R44AI136176-03 FY2022: $988,488 awarded for that fiscal year; activity R44 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Serological Assay for Neutralizing Antitoxin Respon source ↗
Jun 2, 2022 NIH award 5R01AI132207-06 FY2022: $1,008,708 awarded for that fiscal year; activity R01 (OTHER_NIH); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Novel Humanized Tetra-specific Antibody agai source ↗
Apr 15, 2022 NIH award 4R44DK129133-02 FY2022: $855,001 awarded for that fiscal year; activity R44 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. Novel Oral Yeast Immunotherapies for Ulcerative Colit source ↗
Nov 5, 2021 NIH award 5R44AI155277-03 FY2022: $932,749 awarded for that fiscal year; activity R44 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Yeast-based Immunotherapy against Clostridioides di source ↗
Jul 30, 2021 NIH award 2R44AI136176-02 FY2021: $999,996 awarded for that fiscal year; activity R44 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Serological Assay for Neutralizing Antitoxin Respon source ↗
Jun 16, 2021 NIH award 5R01AI132207-05 FY2021: $167,253 awarded for that fiscal year; activity R01 (OTHER_NIH); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Novel Humanized Tetra-specific Antibody agains source ↗
Apr 27, 2021 NIH award 1R44DK129133-01 FY2021: $252,416 awarded for that fiscal year; activity R44 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. Novel Oral Yeast Immunotherapies for Ulcerative Colit source ↗
Mar 30, 2021 NIH award 4R44AI155277-02 FY2021: $554,355 awarded for that fiscal year; activity R44 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Yeast-based Immunotherapy against Clostridioides di source ↗
Aug 11, 2020 NIH award 5R01AI132207-04 FY2020: $2,154,339 awarded for that fiscal year; activity R01 (OTHER_NIH); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Novel Humanized Tetra-specific Antibody agai source ↗
Jul 20, 2020 NIH award 1R44AI155277-01 FY2020: $169,461 awarded for that fiscal year; activity R44 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Yeast-based Immunotherapy against Clostridioides di source ↗
Jun 3, 2019 NIH award 5R01AI132207-03 FY2019: $2,138,618 awarded for that fiscal year; activity R01 (OTHER_NIH); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Novel Humanized Tetra-specific Antibody agai source ↗
May 31, 2018 NIH award 5R01AI132207-02 FY2018: $1,170,960 awarded for that fiscal year; activity R01 (OTHER_NIH); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Novel Humanized Tetra-specific Antibody agai source ↗
Jan 20, 2018 NIH award 1R43AI136176-01 FY2018: $168,931 awarded for that fiscal year; activity R43 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Serological Assay for Neutralizing Antitoxin Respon source ↗
Jan 5, 2018 NIH award 1R43AI136108-01 FY2018: $224,999 awarded for that fiscal year; activity R43 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. Novel Immunotherapies for Comorbidity of Clostridium source ↗
May 29, 2017 NIH award 1R01AI132207-01 FY2017: $1,460,626 awarded for that fiscal year; activity R01 (OTHER_NIH); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Novel Humanized Tetra-specific Antibody agai source ↗
Dec 23, 2016 NIH award 1R43AI129044-01 FY2017: $225,068 awarded for that fiscal year; activity R43 (SBIR); PI YANG, ZHIYONG; recipient as written: FZATA, INC., HALETHORPE, MD. A Yeast based Immunotherapy against Clostridium diffi source ↗